Citius Pharmaceuticals Shares Rise After Announcing Plans for Lymphir Launch

MT Newswires Live

2025/01/08

Citius Pharmaceuticals' (CTXR) shares were up more than 7% in recent Tuesday trading after the company and its Citius Oncology unit announced plans to launch Lymphir commercially in the first half of 2025.

Lymphir is an immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma.

The companies said they have made progress in key launch areas, including securing commercial supply agreements, producing first-year launch supply, developing a patient assistance program, and working on reimbursement pathways.

Price: 4.22, Change: +0.31, Percent Change: +7.80

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2501736907"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501736907\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2501736907?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 02:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501736907","market":"hk","top_or_hot":-1,"title":"Citius Pharmaceuticals Shares Rise After Announcing Plans for Lymphir Launch","media":"MT Newswires Live","content":"<html><body><p> Citius Pharmaceuticals' (CTXR) shares were up more than 7% in recent Tuesday trading after the company and its Citius Oncology unit announced plans to launch Lymphir commercially in the first half of 2025.</p><p>Lymphir is an immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma.</p><p>The companies said they have made progress in key launch areas, including securing commercial supply agreements, producing first-year launch supply, developing a patient assistance program, and working on reimbursement pathways.</p><p>Price: 4.22, Change: +0.31, Percent Change: +7.80</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Pharmaceuticals Shares Rise After Announcing Plans for Lymphir Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Pharmaceuticals Shares Rise After Announcing Plans for Lymphir Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-08 02:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Citius Pharmaceuticals' (CTXR) shares were up more than 7% in recent Tuesday trading after the company and its Citius Oncology unit announced plans to launch Lymphir commercially in the first half of 2025.</p><p>Lymphir is an immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma.</p><p>The companies said they have made progress in key launch areas, including securing commercial supply agreements, producing first-year launch supply, developing a patient assistance program, and working on reimbursement pathways.</p><p>Price: 4.22, Change: +0.31, Percent Change: +7.80</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2501736907","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501736907","pubTimestamp":1736276066,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Citius Pharmaceuticals'  shares were up more than 7% in recent Tuesday trading after the company and its Citius Oncology unit announced plans to launch Lymphir commercially in the first half of 2025.Lymphir is an immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma.The companies said they have made progress in key launch areas, including securing commercial supply agreements, producing first-year launch supply, developing a patient assistance program, and working on reimbursement pathways.Price: 4.22, Change: +0.31, Percent Change: +7.80","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CTXR":"Citius Pharmaceuticals, Inc."},"translate_title":"Citius Pharmaceuticals宣布推出Lymphir计划后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTXR":0.9},"content_text":"Citius Pharmaceuticals' (CTXR) shares were up more than 7% in recent Tuesday trading after the company and its Citius Oncology unit announced plans to launch Lymphir commercially in the first half of 2025.Lymphir is an immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma.The companies said they have made progress in key launch areas, including securing commercial supply agreements, producing first-year launch supply, developing a patient assistance program, and working on reimbursement pathways.Price: 4.22, Change: +0.31, Percent Change: +7.80","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}